Biblio
Export 1296 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is A [Clear All Filters]
“Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “TREM2 variants in Alzheimer's disease.”, N Engl J Med, vol. 368, no. 2, pp. 117-27, 2013.
, “TREM2 variants in Alzheimer's disease.”, N Engl J Med, vol. 368, no. 2, pp. 117-27, 2013.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “REST and stress resistance in ageing and Alzheimer's disease.”, Nature, vol. 507, no. 7493, pp. 448-54, 2014.
, “Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”, J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “Acute Exposure of the Mediobasal Hypothalamus to Amyloid-β25-35 Perturbs Hepatic Glucose Metabolism.”, J Alzheimers Dis, 2015.
, “Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.”, J Alzheimers Dis, vol. 48, no. 1, pp. 175-87, 2015.
, “Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.”, J Alzheimers Dis, 2015.
, “Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.”, J Alzheimers Dis, 2015.
, “A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.”, J Alzheimers Dis, vol. 48, no. 2, pp. 443-52, 2015.
, “Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).”, J Alzheimers Dis, vol. 46, no. 3, pp. 687-93, 2015.
, “Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 4, pp. 1009-19, 2015.
, “Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 4, pp. 1009-19, 2015.
, “Cognitive Function and Its Relationship with Macular Pigment Optical Density and Serum Concentrations of its Constituent Carotenoids.”, J Alzheimers Dis, vol. 48, no. 1, pp. 261-77, 2015.
,